Interim report January-September 2008

Interim report January-September 2008

• Group revenues from sales of goods and royalties amounted to 936 (982) MSEK. 

• Earnings per share amounted to 0.78 (3.31*) SEK. 

• Operating income amounted to 100 (381*) MSEK. 

• Revenues within the Esthetics product area amounted to 765 (800) MSEK and
operating income was 177 (487*) MSEK.

• Net income after tax amounted to 77 (329*) MSEK.

July - September
• Group revenues from sales of goods and royalties amounted to 306 (317) MSEK
during the third quarter and operating income amounted to 61 (63) MSEK.
Operating income for the Hospital Healthcare product area amounted to 8 (-13)
MSEK.

• Net income after tax amounted to 45 (45) MSEK during the third quarter.

Events after the end of the period
• Q-Med has given notice to 50 co-workers at the Uppsala facility as part of the
company's work of focusing resources on the Esthetics business. Restructuring
costs are estimated to be 25-30 MSEK and will be charged against income in the
fourth quarter. The measures will lead to savings of approximately 30 MSEK.
(October)


Queries should be addressed to:
Alexander Kotsinas, Vice President and CFO
Tel: +46 (0)73-500 1111
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.